LAIs in a solo practice: buy-and-bill vs specialty pharmacy
Summary
Whether to buy and bill long-acting injectables comes down to cash flow, storage, and how your payers reimburse the drug. Buy-and-bill means you purchase the injectable, hold it in inventory, administer it, and bill the payer for both the drug and the injection — carrying the float and the waste risk yourself. A specialty pharmacy supplies the drug patient-by-patient, keeping it off your books but adding coordination. For most practices of one, the deciding factor is volume: buy-and-bill rewards steady demand.
By Gale Editorial · Updated 2026-07-26. Every figure cited to a dated source. How we write.
The decision in one frame
Whether to buy and bill long-acting injectables is a business decision, not a clinical one, and it turns on three things: your patient volume, your cash flow, and how your payers reimburse the drug. Buy-and-bill means you purchase the injectable, hold it as inventory, administer it, and bill for both the drug and the injection. A specialty pharmacy instead supplies the drug patient-by-patient, keeping it off your books. For a practice of one, volume usually decides it.
There is no universally right answer, and the honest version of this decision names the tradeoffs rather than selling one model. Buy-and-bill can pay off when demand is steady and predictable; a specialty-pharmacy route lowers the risk and the up-front outlay when it is not. Run the numbers with your own patient panel before committing to inventory.
What buy-and-bill actually is
Buy-and-bill is exactly what it sounds like: you buy the drug from a distributor, keep it in stock, administer it in your office, and then bill the payer for the product and for administering it. The drug lives on your books as inventory and as an expense until it is used and reimbursed, so you carry the cost between purchase and payment. That float, and the paperwork behind it, is the model's real weight.
Not every product is even eligible for the model. Some drugs carry a REMS that routes them only through a certified pharmacy, which forecloses ordinary buy-and-bill for that product 1Ref 1U.S. Food and Drug Administration (2026).Risk Evaluation and Mitigation Strategies (REMS).That certain products carry a REMS routing them only through a certified pharmacy, which forecloses ordinary buy-and-bill for that product (as with esketamine). — the same channel constraint that shapes esketamine. On the billing side, buy-and-bill runs on the drug's own supply code plus an administration charge, and getting those units right is where the buy-and-bill and cpt-coding mechanics matter most; a miscounted unit is a denial or an overpayment.
The specialty-pharmacy alternative (white and brown bagging)
The specialty-pharmacy route keeps the drug off your books entirely. The pharmacy dispenses the specific patient's dose and ships it — to the patient (brown bagging) or directly to your office for that patient (white bagging) — and you administer what arrives. You never purchase inventory, never carry the float, and never eat the cost of a wasted or expired vial. In exchange, you take on coordination: the order, the delivery timing, and the storage until the appointment.
Some payers actively prefer or even mandate the specialty-pharmacy channel for high-cost injectables, and some patients' plans route the drug that way regardless of your preference. Verify the patient's benefit before you assume either model, because the plan may make the choice for you. The tradeoff is real: less financial risk, more moving parts to coordinate patient-by-patient, and a delivery you have to receive and store correctly each time.
The economics, honestly
The economics come down to spread, float, and waste, and none of them favors a low-volume practice. In buy-and-bill, your margin is whatever the reimbursement exceeds your acquisition cost, minus the money tied up while you wait to be paid and minus any product you buy but never bill. A single wasted high-cost vial can erase the spread on several successful ones. Steady volume smooths all of this; sporadic use magnifies every downside.
This is the same buy vs build instinct that shapes bigger practice decisions, scaled down to a single drug line: do you own the asset and its risks, or rent the capability and pay for the convenience? Model it honestly with your real numbers — expected doses per month, your acquisition cost, the payer's allowed amount, and a realistic waste rate — before you commit shelf space and cash to inventory. If the math is close, the lower-risk specialty-pharmacy route usually wins for a practice of one.
Storage, waste, and the physical logistics
Physical logistics decide whether buy-and-bill is even feasible in your space. Injectables have storage requirements — many need refrigeration and a monitored cold chain, and all have expiration dates you have to track — so you need reliable, temperature-controlled storage and a system that uses older stock first. A power outage or a failed refrigerator is not a nuisance; it can be a shelf of unusable, unbillable product. Size your inventory to your real turnover, not your optimism.
Keep the buy-and-bill inventory logically separate from any drug samples you hold, since the two follow different rules for storage, tracking, and documentation. Log receipt, storage temperature, administration, and any waste for each unit, so every vial can be traced from purchase to patient. That trail is what makes the model auditable — and it is exactly the discipline that lets you spot the slow leak of expired product before it becomes a real loss.
Controlled-substance and REMS wrinkles
Most LAIs a solo psychiatric prescriber stocks are antipsychotics, but the category also includes extended-release buprenorphine for opioid use disorder — and controlled-substance injectables carry a second rulebook. Since 2023, any prescriber with Schedule III authority and a current DEA registration may treat opioid use disorder office-based after a one-time training attestation 2Ref 2Substance Abuse and Mental Health Services Administration (2026).Buprenorphine.That since 2023 any prescriber with Schedule III authority and a current DEA registration may treat opioid use disorder office-based after a one-time training attestation, bringing office-based extended-release buprenorphine within reach of solo practices., which put office-based extended-release buprenorphine within reach of far more solo practices. But controlled status pulls in DEA handling and, in most states, a PDMP check 3Ref 3PDMP Training and Technical Assistance Center (2026).Prescription Drug Monitoring Program Training and Technical Assistance Center.That controlled-substance injectables require a PDMP check where the state mandates one, with the requirement varying by state..
For a controlled LAI, the buy-and-bill inventory questions stack on top of the controlled-substance recordkeeping: secure storage, reconcilable counts, and a documented PDMP query where your state requires one 3Ref 3PDMP Training and Technical Assistance Center (2026).Prescription Drug Monitoring Program Training and Technical Assistance Center.That controlled-substance injectables require a PDMP check where the state mandates one, with the requirement varying by state.. And where a product is REMS-gated rather than controlled, the acquisition channel may be fixed for you — the constraint that reshapes esketamine into a certified-pharmacy service rather than a buy-and-bill one. Confirm both the schedule and any REMS before you decide how to source a given injectable.
If you prescribe by telehealth
If you prescribe primarily by telehealth, the injection is the one part that cannot be virtual — someone has to administer it in person. Telepsychiatry carries the assessment, the shared decision, and the follow-up well 4Ref 4American Psychiatric Association (2026).Telepsychiatry Toolkit.That telepsychiatry carries the assessment, shared decision, and follow-up for a telehealth prescriber while the injection itself must be administered in person., but the shot itself needs a physical site: your office on an in-person day, a partnering clinic, or a pharmacy that administers. Decide who injects and where before you start a patient on an LAI, not after the first dose is due.
This is a scheduling problem as much as a clinical one. Fitting injection days into the solo prescriber's schedule, coordinating delivery to match the appointment, and tying the injection to your refill policy so a missed dose triggers outreach all keep an LAI program from drifting. The same who-is-due tracking applies to labs without a health system for the patients whose medications need monitoring alongside the injection. Build the operational spine first; the clinical benefit of an LAI only lands if the logistics hold.
Common questions
Run your practice on Gale
The software is free. Gale earns one flat 3.5% all-in per paid transaction — only on transactions that actually pay. No subscription, no setup fee, no network cut.
Start or manage a practice →References
- 1.U.S. Food and Drug Administration (2026). Risk Evaluation and Mitigation Strategies (REMS). U.S. Food and Drug Administration. link ✓That certain products carry a REMS routing them only through a certified pharmacy, which forecloses ordinary buy-and-bill for that product (as with esketamine).
- 2.Substance Abuse and Mental Health Services Administration (2026). Buprenorphine. SAMHSA. link ✓That since 2023 any prescriber with Schedule III authority and a current DEA registration may treat opioid use disorder office-based after a one-time training attestation, bringing office-based extended-release buprenorphine within reach of solo practices.
- 3.PDMP Training and Technical Assistance Center (2026). Prescription Drug Monitoring Program Training and Technical Assistance Center. PDMP TTAC (Brandeis University, BJA-funded). link ✓That controlled-substance injectables require a PDMP check where the state mandates one, with the requirement varying by state.
- 4.American Psychiatric Association (2026). Telepsychiatry Toolkit. American Psychiatric Association. link ✓That telepsychiatry carries the assessment, shared decision, and follow-up for a telehealth prescriber while the injection itself must be administered in person.
https://www.gale.care/for-providers/bhp-lai-buy-and-bill · 4 sources. Competitor details are cited to dated public sources and maintained as they change; figures are estimates, not commitments. Synthetic demonstration.